# Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

> **NCT01835236** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 208 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Vinorelbine
- **DRUG:** T-DM1

## Key facts

- **NCT ID:** NCT01835236
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-03
- **Primary completion:** 2018-01-11
- **Final completion:** 2020-05-26
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01835236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01835236, "Trastuzumab & Pertuzumab Followed by T-DM1 in MBC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01835236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*